LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that five data presentations, of which three are oral presentations, will be featured at the upcoming 27th congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Melbourne, Australia from July 6 – 10, 2019.
"The data to be presented at ISTH showcase our gene therapy expertise in hemophilia B with both long-term safety and durability from our ongoing Phase 1-2 study of AMT-060 , and up to 9 months of safety and FIX activity in the Phase IIb dose-confirmation study of AMT-061,” stated Matt Kapusta, chief executive officer at uniQure. “We also are very pleased to have an oral presentation on our novel gene therapy approach to treat hemophilia A and look forward to presenting these data at the conference.”
Specific details on uniQure’s presentations at ISTH include:
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. www.uniQure.com
uniQure Contacts:
FOR INVESTORS: | FOR MEDIA: | |||
Maria E. Cantor | Eva M. Mulder | Tom Malone | ||
Direct: 339-970-7536 | Direct: +31 20 240 6103 | Direct: 339-970-7558 | ||
Mobile: 617-680-9452 | Mobile: +31 6 52 33 15 79 | Mobile:339-223-8541 | ||
m.cantor@uniQure.com | e.mulder@uniQure.com | t.malone@uniQure.com |